

# HBM UCITS (Lux) Funds-HBM Global Healthcare Fund-A Cap-EUR

ISIN (LU1540961163)


## INVESTMENT OBJECTIVE

The investment objective of HBM Global Healthcare Fund (the "Sub-Fund") is to achieve long-term capital gains, by pursuing a long/short strategy in the "healthcare" market, and to generate a value trend that exceeds the performance of the SOFR.

To attain its investment objective, the Sub-Fund will mainly be exposed to equities and equity-related securities of small-cap, mid-cap, and blue chip companies worldwide in the fields of pharmaceutical, biotechnological, and medical technologies and of companies engaged in medical services, equipment, and accessories worldwide and/or of companies whose principal activity is to hold interest positions in or finance such companies. Traditional long positions are coupled with (synthetic) long and short positions achieved through the use of financial derivative instruments (such as contracts for difference).


The Sub-Fund may also have an exposure to the healthcare equities via investments in UCIs (up to 10% of its net assets).

## INDEXED PERFORMANCE




Data Source: FundPartner Solutions (Europe) S.A. – Part of Pictet Group

## QUARTERLY PERFORMANCE




Data Source: FundPartner Solutions (Europe) S.A. – Part of Pictet Group

## GEOGRAPHICAL BREAKDOWN (as at 30/09/2024)



The above breakdown information is expected to fluctuate over time.  
Data Source: FundPartner Solutions (Europe) S.A. – Part of Pictet Group

## 10 LARGEST HOLDINGS (as at 30/09/2024)



The above breakdown information is expected to fluctuate over time.  
Data Source: FundPartner Solutions (Europe) S.A. – Part of Pictet Group

## RISK LEVEL



The rating is based on historical data and may not be a reliable indication of the future risk profile. The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

## PERFORMANCE vs EuroShort-Term Rate (ESTR)

	Fund		Index	
	Cumulative	Index	Annualised	Index
YTD	11.56%	2.90%	-	-
1 month	-3.45%	0.30%	-	-
3 months	3.62%	0.93%	-	-
1 year	23.39%	3.90%	23.39%	3.90%
3 years	-3.29%	6.05%	-1.11%	1.98%
5 years	33.41%	5.02%	5.93%	0.98%
Since inception	36.23%	4.66%	5.34%	0.77%

	Fund		Index	
	Yearly	Index	September to September	Index
2023	3.64%	3.23%	23.39%	3.90%
2022	-19.10%	-0.02%	0.85%	2.55%
2021	13.38%	-0.57%	-22.28%	-0.46%
2020	14.47%	-0.44%	18.55%	-0.56%
2019	16.50%	-0.40%	16.37%	-0.41%

24 Oct 2018 to 31 Dec 2021, 3-months LIBOR EUR  
Past performance must not be considered an indicator or guarantee of future performance. All performance data are based on net performance and take no account of commissions, fees or other costs charged when units are issued and redeemed. The return of the Fund may go down as well as up due to changes in rates of exchange between currencies. Future performance is subject to taxation which depends on the personal situation of each investor and which may change in the future  
Data Source: FundPartner Solutions (Europe) S.A. – Part of Pictet Group

## TECHNICAL INFORMATION\* (as at 30/09/2024)

NAV	EUR 136.23	Dividend	Reinvested
AuM (in mio.)	EUR 17.37	Number of positions	36
Max. drawup	35.58%	Max. drawdown	-29.27%
Volatility	15.85%	Tracking error	15.73%
Sharpe ratio	-0.19	Information ratio	-0.20
Jensen alpha	-3.73%	Beta	-106.63
Correlation	-0.24	R-square	0.06
Net Exposure**	91.70%		

\* Historical statistics are calculated over 3 years.  
\*\* Source: figures calculated from Bloomberg.  
Data Source: FundPartner Solutions (Europe) S.A. – Part of Pictet Group

# HBM UCITS (Lux) Funds-HBM Global Healthcare Fund-A Cap-EUR

## ISIN (LU1540961163)

### Overview

While September has historically been the worst month for stocks, the major indexes bucked the trend this year, with the MSCI World Index (+1.7%) pushing through to new highs at the end of the month - to finish the quarter with a gain of 6.5%. September started no different to August, with some notable selling early on then giving way to a rally later in the month. The negative stock price reaction during the early days was driven by concerns over economic growth after a slew of soft data, especially on the employment market, which showed smaller-than-expected jobs creation, and a continued contraction in manufacturing activity. Overall, investors gained confidence on the US Fed's recent pivot on interest rates and on the belief that the Central Bank might remain quite dovish over the remaining months of 2024 and next year. In a bold move, the US Fed lowered rates by half a percentage point mid-month, a decrease that exceeded earlier expectations. Chair Powell characterised the substantial rate cut as a "recalibration" rather than a hasty response to an emergency. Investors interpreted this as a sign that the Fed is committed to establishing a new "neutral" stance without necessarily being compelled by a weakening economy. Sector performance diverged in the month: Consumer discretionary and utilities led the market sectors, while real estate, energy and healthcare stocks (MSCI World Health Care Index: -3.1%) posted losses in September. The macro backdrop and re-emerging risk-on sentiment last month benefitted growth sectors at the expense of the more defensive segments of the market such as healthcare. Similar dynamic was also present within the healthcare sector: Cyclical and higher-beta segments (medical equipment & suppliers, elective procedures, life sciences & tools) led in performance while more defensive sleeves like pharma and managed care/insurers lagged. The biotechnology sector was not (yet) a beneficiary of the Fed's pivot on interest rates. Clinical and regulatory developments were rather disappointing (e.g. Novo, Regeneron, Biomarin) and larger M&A activities remained absent, although confidence in the sector is returning, as reflected in higher levels of financing and tentative signs that the IPO window is re-opening.

### Portfolio performance

The NAV of the main share class (A Cap USD) decreased by 3.3%, marginally underperforming the broader sector index MSCI World Health Care Sector (-3.1%). Exact Sciences (+10.4%) and Natera (+7.3%) were among the most positive contributors to NAV. Shares in the cancer-screening and diagnostic testing company firm Exact moved higher post quarterly results, encouraging data in blood-based colorectal cancer screening at ESMO 2024 (European Society for Medical Oncology) and ahead of a regulatory catalyst. Natera, a leading player in the diagnostics industry with a core focus on the field of cell-free DNA testing, saw a continuation of the rally in its share price. In strong contrast, shares of NeoGenomics (-11.7%) suffered from a legal setback following its competitor Natera won a permanent injunction that will prevent NeoGenomics from selling its RaDaR assay in the US. The company said it is developing a new assay that will not infringe Natera's IP (intellectual property). Shares of companies exposed to the obesity space had a challenging month: Larger caps Novo (-16.1%), Eli Lilly (-7.7%), Roche (-5.8%) plunged in sympathy with smaller cap companies Corbus (-66.3%) and Gubra (-9.9%). Novo Nordisk announced that CB1 drug (monlunabant), in phase IIa clinical testing, showed weight loss at the lower-end of expectations of 6%. More concerning was the disclosure of mild to moderate neuropsychiatric side effects, primarily anxiety, irritability, and sleep disturbances, that were more frequent and dose dependent with monlunabant compared to placebo. Shares of Corbus, which has a pipeline consist of a potential CB1 drug in pre-clinical testing, lost two-thirds of their value. Analysts believe the safety profile for Corbus and Novo second generation peripherally restricted CB1s must be clean given prior market withdrawal of first generation CB1 Rimonabant. Further, Novo was under pressure after comments that diabetes and obesity flagship Ozempic could be targeted for next round of IRA (Inflation Reduction Act) related price controls. Roche traded lower amid gastrointestinal side effects from its obesity drug CT-388, raising concerns among investors about the drug's future market potential. AstraZeneca (-12.7%) was the largest negative contributor to NAV, among large pharma positions in the portfolio. Astra and Daiichi Sankyo's investigational antibody-drug conjugate (ADC) datopotamab deruxtecan suffered a double blow in late-stage trials. It first failed to significantly outperform the standard-of-care chemotherapy docetaxel in treating NSCLC (non-small-cell lung cancer). And then it failed to show notable improvement in overall survival compared to chemotherapy in breast cancer. Analysts had expected datopotamab deruxtecan to potentially become one of Astra's best-selling drugs.

### Portfolio changes

We made some incremental changes to the portfolio in September, mainly focused on profit-taking in certain high performing names, managing the risk profile of the portfolio and adding exposure to some specific biopharma stocks where we see attractive risk/return potential.

### Fund Outlook

Equity markets delivered an impressive comeback in the second-half of last month. The prospect of lower short-term borrowing rates has lent support to stock valuations. Interestingly, the recently closed third quarter 2024 saw a shift in market leadership. Value stocks and small to mid-cap companies outperformed their growth and large-cap counterparts, potentially signalling a broadening of the market rally beyond the dominant tech sector. A "soft landing" for the US economy, where inflation has largely been tamed from highs without triggering a recession is widely considered the base case scenario. This optimism was bolstered by a healthy growth of the gross domestic product number (GDP). The latest September Job's report showed the labor market remains robust, even amid signs it has cooled. Market participants anticipate further easing, with expectations of another 50 basis point cut before the year's end. However, these expectations may be more aggressive than a "soft landing" scenario typically warrants. We should be aware that this divergence between market expectations and economic realities could potentially lead to volatility if the Fed's actual policy path deviates from these optimistic projections. It does also mean that investors will be paying even closer attention to upcoming economic data and focus much of their attention on the Fed's monetary policy path forward. Regardless of the direction of travel for the broader economy, we continue to believe that the economic sensitivity of the healthcare sector remains low relative to other sectors, while the innovation and growth potential remains high.

### GENERAL INFORMATION

Fund manager	HBM Partners AG
Custodian Bank	Bank Pictet & Cie (Europe) AG, Succursale de Luxembourg
Legal status	UCITS V Luxembourg Sicav
Country of registration	AT, CH, DE, FR, GB, LI, LU
Inception Date	24 October 2018
Multiclass	A Cap-USD, A Cap-EUR, P Cap-USD
NAV valuation	Daily, "forward pricing"
Order Deadline	T-1 day / 16:00 CET
Management fee	1.60% p.a.
TER	3.36% p.a.
Max. subscription fee	3.00% to the benefit of the intermediaries
Max. redemption fee	0.00% to the benefit of the intermediaries
ISIN	LU1540961163
Bloomberg	HBMHACE LX
Publication media	www.fundinfo.com
Management Company	FundPartner Solutions (Europe) S.A. – Part of Pictet Group
Domicile	Luxembourg
Base Currency	USD

Not all costs are displayed. For further information, please refer to the prospectus  
Data Source: FundPartner Solutions (Europe) S.A. – Part of Pictet Group

---

# HBM UCITS (Lux) Funds-HBM Global Healthcare Fund-A Cap-EUR

## ISIN (LU1540961163)

---

MSCI:

Source and Copyright: MSCI ESG Rating: Produced by MSCI ESG, Research as of May 31, 2023

Swiss representation agent: FundPartner Solutions (Suisse) SA, route des Acacias 60, CH-1211 Geneva / Swiss paying agent: Banque Pictet & Cie SA, Route des Acacias 60, CH-1211 Geneva 73 / Paying and information Agent in Austria: Erste Bank der oesterreichischen Sparkassen AG, Am Belvedere 1, 1100 Wien, Österreich / Paying and information agent in Germany: Deutsche Bank Aktiengesellschaft, Taunusanlage 12, 60325 Frankfurt am Main, Federal Republic of Germany / Paying and information agent in Liechtenstein: LLB Fund Services AG, Aulestrasse 80, P. O. Box 1238, 9490 Vaduz, Liechtenstein / Centralising agent in France: BNP Paribas Securities Services Paris, 9 rue du Débarcadère, 93500 Pantin / Facilities Agent in the United Kingdom: 42 Brook Street, W1K5DB London.

The fund mentioned in the present document (hereinafter the "Fund") does not guarantee that the data contained in this report (hereinafter the "Data") are complete, accurate, or free of errors or omissions. The Fund is not liable for this report under any circumstances. This marketing communication is distributed by the Fund or authorised distribution agencies for information purposes only and does not constitute an offer to subscribe for shares of the Fund. Subscriptions of the Fund, an investment fund under Luxembourg law (SICAV), should in any event be made solely on the basis of the current offering prospectus, the Key Information Document ("KID"), the articles of incorporation and the most recent annual or semi-annual report and after seeking the advice of an independent finance, legal, accounting and tax specialist. Interested parties may obtain the abovementioned documents in English, German and French, free of charge from the local entity mentioned above and from the offices of the Fund at 15, avenue John F. Kennedy, L-1855 Luxembourg. You can obtain a summary of investors rights to the following link : <https://www.pictet.com/content/dam/www/documents/legal-and-notes/fundpartner-solutions/fps-summary-of-Investors-rights.pdf.coredownload.pdf>.

The Data Providers do not guarantee the adequacy, accuracy, timeliness or completeness of their data and information (hereinafter the "Third Party Data").

The Data Providers do not make any representation regarding the advisability of any investment and do not sponsor, promote, issue, sell or otherwise recommend or endorse any investment. An investment in a sub-fund of the Fund carries various risks which are explained in the offering prospectus.